Biologics manufacturing is getting into a brand new part the place agility and proximity matter as a lot as scale. For many years, the business relied on the philosophy that “greater is best,” setting up large, centralized amenities to drive down unit prices. Nonetheless, the bottom is shifting beneath our toes.
The increasing portfolio of biologic medication dictates this shift. Over the previous 15 years, the variety of proteins getting into Section 1 medical trials has doubled, and 50 p.c of latest biologics are uncommon or orphan medicationhighlighting the necessity for versatile manufacturing. We’re shifting away from a blockbuster-only world towards one outlined by fragmentation and precision. In the meantime, biomanufacturing infrastructure has change into more and more restricted.
To fulfill this accelerating demand for bioproducts, biotech innovators want high-quality, cost-effective approaches to manufacturing and improvements that allow small-volume manufacturing capability. Whereas conventional centralized amenities will proceed to play a significant function, early market and regulatory indicators level to a rising shift towards smaller, regional websites that may reply quicker to demand, provide disruption, and rising therapeutic wants.
The rising demand for customized and rare-disease therapies necessitates a transition towards regulatory frameworks that assist distributed biomanufacturing by way of technological innovation. Present geopolitical instability underscores that distributed manufacturing is crucial for sustaining each nation’s well being resilience and guaranteeing affected person entry.
Centralized manufacturing is displaying its limits
The “mega-factory” mannequin was constructed for a steady world, however stability is presently in brief provide. Ongoing provide chain disruptions and element shortages proceed to reveal weaknesses in single-site, globally dependent operations.
The affect on sufferers is measurable and alarming. Lengthy-standing, persistent shortages account for greater than 90% of all drug shortages in the US, with the common length of present shortages now over 4 years.
Once we rely closely on centralization, medical and business packages are more and more slowed as a result of important supplies, tools, or outsourced processes change into bottlenecks. As an illustration, delays in uncooked materials supply can push crucial biologics shipments again by months, impacting affected person entry.
Giant amenities stay important for high-volume indications, however their dimension and complexity make speedy adaptation tough, forcing organizations to decide on between throughput and adaptability. It sometimes takes three to 5 years and over $200 million to construct typical biomanufacturing amenities. A majority of these amenities are sometimes constructed for a single product kind and can’t quickly adapt to adjustments in product demand.
These pressures are forcing corporations to rethink whether or not centralization can meet the tempo and variety of contemporary biologics pipelines. Because the market demand for precision medication, uncommon illness therapeutics, and small-batch biologics change into extra prevalent, centralized amenities alone could not suffice to satisfy numerous, pressing affected person wants.
The rise of versatile biomanufacturing
The answer to this rigidity lies within the adoption of intensified and steady processing. Advances in modular, closed, and automatic methods permit smaller amenities to function with consistency and decrease staffing necessities.
Steady manufacturing provides substantial advantagestogether with a lowered tools footprint of as much as 70%, a 3- to 5-fold improve in volumetric productiveness, enhanced product high quality consistency, and facility price reductions of 30–50% in comparison with conventional batch processes. These metrics make distributed manufacturing economically possible and operationally advantageous.
Importantly, international regulators are more and more accepting modular, single-use, and steady manufacturing methods for medical and business provide, lowering obstacles for regional deployment. We’re seeing modern producers worldwide show that this strategy delivers high-quality therapeutics and is sweet enterprise.
For instance, in Q3 2025, WuXi Biologics introduced that its Eire facility was accepted by European Medicines Company (EMA) as a business manufacturing website for a world consumer’s biologic–one of many largest cell tradition processes utilizing single-use expertise worldwide. This website deploys the WuXiUp platform for automated steady drug substance (DS) manufacturing at pilot-scale, demonstrating that single-use steady tech can meet rigorous regulatory requirements.
One other instance is Enzene Biosciences’ EnzeneX expertise, which was the primary fully-connected steady manufacturing (FCCM) strategy validated for business biologics provide. Enzene just lately (September 2025) inaugurated a brand new facility in Hopewell, New Jersey that can deploy the EnzeneX platform. This standardization between websites permits them to switch a course of from their R&D middle in Pune, India, to their New Jersey location with minimal friction, epitomizing the “copy-exact” mannequin needed for a distributed community.
Lastly, BiosanaPharma has deployed their “3C” course of — Steady, Closed, and Compact — to attain an enormous milestone by producing the primary monoclonal antibody (a biosimilar of omalizumab) manufactured with a completely steady course of to enter medical trials in Australia. They’re now working to assist third eventstogether with biologic innovators and CDMOs, deploy the 3C platform to get improved effectivity from present amenities.
Conclusion: A turning level for biomanufacturing
Personalised and highly-targeted therapeutics have gotten extra widespread, making native or regional manufacturing more and more beneficial for quicker affected person entry. This underscores how a hybrid community combining massive, centralized crops coupled with versatile regional websites will outline the following period of resilient biomanufacturing.
Biomanufacturing won’t change into decentralized instantly, however the traits are clear. Rising applied sciences, regulatory developments, and shifts in therapeutic demand are driving the business towards a extra distributed strategy. Crucially, regulators and producers should companion to outline high quality danger administration requirements for distributed manufacturing — an important step in securing international affected person entry to biologics.
Firms that start getting ready now by modernizing platforms, exploring modular facility designs, and pinpointing the place regional capability might strengthen resilience will probably be higher positioned to satisfy future wants. The subsequent part of biologics manufacturing will probably be outlined by flexibility, proximity, and the flexibility to ship therapies to sufferers extra shortly.
Photograph: nevarpp, Getty Pictures
Dr. Kerry Love is the co-founder and CEO of Sunflower Therapeuticsa women-owned and led biotechnology firm delivering next-generation protein manufacturing options that anybody can use to create modern new medicines, vaccines, meals, and different bio-produced supplies. Kerry is an natural chemist by coaching, performing her doctoral research at MIT, and a biotech entrepreneur at coronary heart, having based two corporations and contributed to the beginning of many extra over the previous twenty years.
This publish seems by way of the MedCity Influencers program. Anybody can publish their perspective on enterprise and innovation in healthcare on MedCity Information by way of MedCity Influencers. Click on right here to learn the way.
